{"transactions":[{"id":726388,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-25T22:59:52.000Z","date":"2026-06-23","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":20000,"derivative":{"exercise_price":2.15,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-26-283209","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526283209/ownership.xml","form_type":"4"}},{"id":726387,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-25T22:59:52.000Z","date":"2026-06-23","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":85000,"source":{"system":"sec-edgar","filing":"0001193125-26-283209","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526283209/ownership.xml","form_type":"4"}},{"id":769768,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T20:24:58.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":55150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":55150,"derivative":{"exercise_price":3.33,"expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":55150},"source":{"system":"sec-edgar","filing":"0001193125-26-232657","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000119312526232657/ownership.xml","form_type":"4"}},{"id":873805,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-02T21:30:36.000Z","date":"2026-02-27","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":5,"value":25000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on February 27, 2026."}],"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001193125-26-085514","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000119312526085514/ownership.xml","form_type":"4"}},{"id":1109814,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T00:24:33.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 12, 2026, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0000950170-25-087009","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000095017025087009/ownership.xml","form_type":"4"}},{"id":1148998,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-14T20:32:51.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 13, 2026 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":19000,"derivative":{"exercise_price":1.875,"expiration_date":"2035-05-13","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001062993-25-009377","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000106299325009377/form4.xml","form_type":"4"}},{"id":1496445,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-31T20:58:04.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 29, 2025 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":19000,"derivative":{"exercise_price":7.07,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001062993-24-011572","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000106299324011572/form4.xml","form_type":"4"}},{"id":1497878,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-30T20:15:59.000Z","date":"2024-05-29","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on May 29, 2025, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":55000,"source":{"system":"sec-edgar","filing":"0000950170-24-066617","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000095017024066617/ownership.xml","form_type":"4"}},{"id":1640756,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T21:21:16.000Z","date":"2024-02-14","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":11,"value":22000.0,"ownership":{"direct":true},"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001062993-24-003312","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000106299324003312/form4.xml","form_type":"4"}},{"id":1671919,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T22:27:31.000Z","date":"2024-01-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":179390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the \"Cash Consideration\"), and (b) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a \"Transition Award\") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The ordinary shares, nominal value GBP per share (the \"Ordinary Shares\") may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents ten Ordinary Shares."}],"balance_after":0,"derivative":{"exercise_price":0.58,"expiration_date":"2033-02-28","underlying":"Ordinary Shares","underlying_shares":179390},"source":{"system":"sec-edgar","filing":"0000950170-24-007078","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000095017024007078/ownership.xml","form_type":"4"}},{"id":1671918,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T22:27:31.000Z","date":"2024-01-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":405590,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the \"Cash Consideration\"), and (b) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a \"Transition Award\") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The ordinary shares, nominal value GBP per share (the \"Ordinary Shares\") may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents ten Ordinary Shares."}],"balance_after":0,"derivative":{"exercise_price":0.464,"expiration_date":"2033-02-28","underlying":"Ordinary Shares","underlying_shares":405590},"source":{"system":"sec-edgar","filing":"0000950170-24-007078","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000095017024007078/ownership.xml","form_type":"4"}},{"id":1671917,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T22:27:31.000Z","date":"2024-01-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the \"Cash Consideration\"), and (b) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a \"Transition Award\") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The ordinary shares, nominal value GBP per share (the \"Ordinary Shares\") may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents ten Ordinary Shares."}],"balance_after":0,"derivative":{"exercise_price":0.58,"expiration_date":"2032-10-03","underlying":"Ordinary Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-24-007078","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000095017024007078/ownership.xml","form_type":"4"}},{"id":1671916,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T22:27:31.000Z","date":"2024-01-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":457800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the \"Cash Consideration\"), and (b) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a \"Transition Award\") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The ordinary shares, nominal value GBP per share (the \"Ordinary Shares\") may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents ten Ordinary Shares."}],"balance_after":0,"derivative":{"exercise_price":0.58,"expiration_date":"2032-10-03","underlying":"Ordinary Shares","underlying_shares":457800},"source":{"system":"sec-edgar","filing":"0000950170-24-007078","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000095017024007078/ownership.xml","form_type":"4"}},{"id":1671915,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T22:27:31.000Z","date":"2024-01-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":335000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the \"Cash Consideration\"), and (b) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a \"Transition Award\") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The ordinary shares, nominal value GBP per share (the \"Ordinary Shares\") may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents ten Ordinary Shares."}],"balance_after":0,"derivative":{"exercise_price":0.459,"expiration_date":"2032-05-31","underlying":"Ordinary Shares","underlying_shares":335000},"source":{"system":"sec-edgar","filing":"0000950170-24-007078","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000095017024007078/ownership.xml","form_type":"4"}},{"id":1671914,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T22:27:31.000Z","date":"2024-01-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27730,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the \"Cash Consideration\"), and (b) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a \"Transition Award\") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The ordinary shares, nominal value GBP per share (the \"Ordinary Shares\") may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents ten Ordinary Shares."}],"balance_after":0,"derivative":{"exercise_price":0.58,"expiration_date":"2031-01-31","underlying":"Ordinary Shares","underlying_shares":27730},"source":{"system":"sec-edgar","filing":"0000950170-24-007078","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000095017024007078/ownership.xml","form_type":"4"}},{"id":1671913,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T22:27:31.000Z","date":"2024-01-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":309990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the \"Cash Consideration\"), and (b) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a \"Transition Award\") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The ordinary shares, nominal value GBP per share (the \"Ordinary Shares\") may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents ten Ordinary Shares."}],"balance_after":0,"derivative":{"exercise_price":0.58,"expiration_date":"2031-01-31","underlying":"Ordinary Shares","underlying_shares":309990},"source":{"system":"sec-edgar","filing":"0000950170-24-007078","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000095017024007078/ownership.xml","form_type":"4"}},{"id":1671912,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T22:27:31.000Z","date":"2024-01-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":149990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the \"Cash Consideration\"), and (b) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a \"Transition Award\") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The ordinary shares, nominal value GBP per share (the \"Ordinary Shares\") may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents ten Ordinary Shares."}],"balance_after":0,"derivative":{"exercise_price":0.58,"expiration_date":"2030-03-31","underlying":"Ordinary Shares","underlying_shares":149990},"source":{"system":"sec-edgar","filing":"0000950170-24-007078","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000095017024007078/ownership.xml","form_type":"4"}},{"id":1671911,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T22:27:31.000Z","date":"2024-01-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":199990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the \"Cash Consideration\"), and (b) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a \"Transition Award\") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The ordinary shares, nominal value GBP per share (the \"Ordinary Shares\") may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents ten Ordinary Shares."}],"balance_after":0,"derivative":{"exercise_price":0.58,"expiration_date":"2030-01-01","underlying":"Ordinary Shares","underlying_shares":199990},"source":{"system":"sec-edgar","filing":"0000950170-24-007078","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000095017024007078/ownership.xml","form_type":"4"}},{"id":1671910,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T22:27:31.000Z","date":"2024-01-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":99980,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the \"Cash Consideration\"), and (b) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, the vested portions of these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. In addition, the unvested portions of these options were converted into a transition award (each, a \"Transition Award\") representing the right to receive (i) an amount in in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR. Consideration under the Transition Awards shall vest and be paid pursuant to the vesting terms of the original award agreement, subject to the holder's continued service with KKC and its subsidiaries through each applicable vesting date; provided, however that any portion of such Transition Award that remains unvested as of December 31, 2024 will vest in full on such date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The ordinary shares, nominal value GBP per share (the \"Ordinary Shares\") may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents ten Ordinary Shares."}],"balance_after":0,"derivative":{"exercise_price":0.58,"expiration_date":"2029-01-15","underlying":"Ordinary Shares","underlying_shares":99980},"source":{"system":"sec-edgar","filing":"0000950170-24-007078","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000095017024007078/ownership.xml","form_type":"4"}},{"id":1671909,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2024-01-24T22:27:31.000Z","date":"2024-01-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":92081,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares, nominal value GBP per share (the \"Ordinary Shares\") may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents ten Ordinary Shares."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the \"Cash Consideration\"), and (b) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company (\"KKC\") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the \"Company\"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the \"Cash Consideration\"), and (b) one contractual contingent value right (each, a \"CVR\"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-007078","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000095017024007078/ownership.xml","form_type":"4"}},{"id":1762602,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-10T21:39:37.000Z","date":"2023-10-05","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on October 5, 2024, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":35000,"source":{"system":"sec-edgar","filing":"0000950170-23-052715","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000095017023052715/ownership.xml","form_type":"4"}},{"id":1896567,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-11T20:28:50.000Z","date":"2023-05-09","kind":"grant","planned":false,"acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 9, 2024 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":8300,"derivative":{"exercise_price":5.09,"expiration_date":"2033-05-09","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001062993-23-010805","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000106299323010805/form4.xml","form_type":"4"}},{"id":1953886,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-14T12:30:50.000Z","date":"2023-03-10","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option vest and become exercisable in twenty-four (24) equal monthly installments, with the first installment vested on March 1, 2022."}],"balance_after":335000,"derivative":{"exercise_price":0.4591,"expiration_date":"2032-05-31","underlying":"Ordinary Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-018327","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919123018327/doc4.xml","form_type":"4"}},{"id":1953885,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2023-03-14T12:30:50.000Z","date":"2023-03-10","kind":"exercise","acquired":true,"shares":20000,"price":0.4591,"value":9182.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares."}],"balance_after":92081,"source":{"system":"sec-edgar","filing":"0001209191-23-018327","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919123018327/doc4.xml","form_type":"4"}},{"id":1972536,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-03T23:00:29.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":179400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments, with the first installment vesting on April 1, 2023."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":179400,"derivative":{"exercise_price":0.5795,"expiration_date":"2033-02-28","underlying":"Ordinary Shares","underlying_shares":179400},"source":{"system":"sec-edgar","filing":"0001209191-23-015881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919123015881/doc4.xml","form_type":"4"}},{"id":1972535,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-03T23:00:29.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":405600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments, with the first installment vesting on April 1, 2023."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":405600,"derivative":{"exercise_price":0.4636,"expiration_date":"2033-02-28","underlying":"Ordinary Shares","underlying_shares":405600},"source":{"system":"sec-edgar","filing":"0001209191-23-015881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919123015881/doc4.xml","form_type":"4"}},{"id":2019614,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-13T13:09:59.000Z","date":"2023-02-09","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option vest and become exercisable in twenty-four (24) equal monthly installments, with the first installment vested on March 1, 2022."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":355000,"derivative":{"exercise_price":0.4591,"expiration_date":"2032-05-31","underlying":"Ordinary Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-008578","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919123008578/doc4.xml","form_type":"4"}},{"id":2019613,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2023-02-13T13:09:59.000Z","date":"2023-02-09","kind":"exercise","acquired":true,"shares":20000,"price":0.4591,"value":9182.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":72081,"source":{"system":"sec-edgar","filing":"0001209191-23-008578","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919123008578/doc4.xml","form_type":"4"}},{"id":2141172,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T22:11:15.000Z","date":"2022-10-04","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The shares subject to this option vest in equal monthly installments over the two years after July 1, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":75000,"derivative":{"exercise_price":0.58,"expiration_date":"2032-10-03","underlying":"Ordinary Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-22-053005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122053005/doc4.xml","form_type":"4"}},{"id":2141171,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T22:11:15.000Z","date":"2022-10-04","kind":"grant","acquired":true,"shares":457811,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares subject to this option vest in equal monthly installments over the three years after October 4, 2022."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":457811,"derivative":{"exercise_price":0.58,"expiration_date":"2032-10-03","underlying":"Ordinary Shares","underlying_shares":457811},"source":{"system":"sec-edgar","filing":"0001209191-22-053005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122053005/doc4.xml","form_type":"4"}},{"id":2141170,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T22:11:15.000Z","date":"2022-10-04","kind":"grant","acquired":true,"shares":27731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":27731,"derivative":{"exercise_price":0.58,"expiration_date":"2031-01-31","underlying":"Ordinary Shares","underlying_shares":27731},"source":{"system":"sec-edgar","filing":"0001209191-22-053005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122053005/doc4.xml","form_type":"4"}},{"id":2141169,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T22:11:15.000Z","date":"2022-10-04","kind":"disposition_to_issuer","acquired":false,"shares":27731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":5.98,"expiration_date":"2031-01-31","underlying":"Ordinary Shares","underlying_shares":27731},"source":{"system":"sec-edgar","filing":"0001209191-22-053005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122053005/doc4.xml","form_type":"4"}},{"id":2141168,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T22:11:15.000Z","date":"2022-10-04","kind":"grant","acquired":true,"shares":310000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to this option vest in equal monthly installments over the four years after February 1, 2021."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":310000,"derivative":{"exercise_price":0.58,"expiration_date":"2031-01-31","underlying":"Ordinary Shares","underlying_shares":310000},"source":{"system":"sec-edgar","filing":"0001209191-22-053005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122053005/doc4.xml","form_type":"4"}},{"id":2141167,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T22:11:15.000Z","date":"2022-10-04","kind":"disposition_to_issuer","acquired":false,"shares":310000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to this option vest in equal monthly installments over the four years after February 1, 2021."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":5.98,"expiration_date":"2031-01-31","underlying":"Ordinary Shares","underlying_shares":310000},"source":{"system":"sec-edgar","filing":"0001209191-22-053005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122053005/doc4.xml","form_type":"4"}},{"id":2141166,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T22:11:15.000Z","date":"2022-10-04","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option vest in equal monthly installments over the four years after April 1, 2020."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":150000,"derivative":{"exercise_price":0.58,"expiration_date":"2030-03-31","underlying":"Ordinary Shares","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-22-053005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122053005/doc4.xml","form_type":"4"}},{"id":2141165,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T22:11:15.000Z","date":"2022-10-04","kind":"disposition_to_issuer","acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option vest in equal monthly installments over the four years after April 1, 2020."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":7.05,"expiration_date":"2030-03-31","underlying":"Ordinary Shares","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-22-053005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122053005/doc4.xml","form_type":"4"}},{"id":2141164,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T22:11:15.000Z","date":"2022-10-04","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option vest in equal monthly installments over the four years after January 2, 2020."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":200000,"derivative":{"exercise_price":0.58,"expiration_date":"2030-01-01","underlying":"Ordinary Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-22-053005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122053005/doc4.xml","form_type":"4"}},{"id":2141163,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T22:11:15.000Z","date":"2022-10-04","kind":"disposition_to_issuer","acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option vest in equal monthly installments over the four years after January 2, 2020."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":13.58,"expiration_date":"2030-01-01","underlying":"Ordinary Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-22-053005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122053005/doc4.xml","form_type":"4"}},{"id":2141162,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T22:11:15.000Z","date":"2022-10-04","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option vest in equal monthly installments over the four years after January 16, 2019."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":100000,"derivative":{"exercise_price":0.58,"expiration_date":"2029-01-15","underlying":"Ordinary Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-22-053005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122053005/doc4.xml","form_type":"4"}},{"id":2141161,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T22:11:15.000Z","date":"2022-10-04","kind":"disposition_to_issuer","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option vest in equal monthly installments over the four years after January 16, 2019."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":12.54,"expiration_date":"2029-01-15","underlying":"Ordinary Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-22-053005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122053005/doc4.xml","form_type":"4"}},{"id":2141160,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T22:11:15.000Z","date":"2022-10-04","kind":"grant","acquired":true,"shares":184229,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":184229,"derivative":{"exercise_price":0.58,"expiration_date":"2028-09-12","underlying":"Ordinary Shares","underlying_shares":184229},"source":{"system":"sec-edgar","filing":"0001209191-22-053005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122053005/doc4.xml","form_type":"4"}},{"id":2141159,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T22:11:15.000Z","date":"2022-10-04","kind":"disposition_to_issuer","acquired":false,"shares":184229,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":9.06,"expiration_date":"2028-09-12","underlying":"Ordinary Shares","underlying_shares":184229},"source":{"system":"sec-edgar","filing":"0001209191-22-053005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122053005/doc4.xml","form_type":"4"}},{"id":2141158,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T22:11:15.000Z","date":"2022-10-04","kind":"grant","acquired":true,"shares":426185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":426185,"derivative":{"exercise_price":0.58,"expiration_date":"2028-02-06","underlying":"Ordinary Shares","underlying_shares":426185},"source":{"system":"sec-edgar","filing":"0001209191-22-053005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122053005/doc4.xml","form_type":"4"}},{"id":2141157,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T22:11:15.000Z","date":"2022-10-04","kind":"disposition_to_issuer","acquired":false,"shares":426185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 4, 2022, the Compensation Committee of the Issuer's Board of Directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.44,"expiration_date":"2028-02-06","underlying":"Ordinary Shares","underlying_shares":426185},"source":{"system":"sec-edgar","filing":"0001209191-22-053005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122053005/doc4.xml","form_type":"4"}},{"id":2155773,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-19T21:40:47.000Z","date":"2022-09-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on September 15, 2023, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0000899243-22-031498","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924322031498/doc4.xml","form_type":"4"}},{"id":2244201,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T12:00:15.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in twenty-four (24) equal monthly installments, with the first installment vested on March 1, 2022."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":375000,"derivative":{"exercise_price":0.4591,"expiration_date":"2032-05-31","underlying":"Ordinary Shares","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001209191-22-033780","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122033780/doc4.xml","form_type":"4"}},{"id":2273296,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-13T00:26:59.000Z","date":"2022-05-10","kind":"grant","acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest on the earlier of (a) May 10, 2023 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":8300,"derivative":{"exercise_price":2.92,"expiration_date":"2032-05-10","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001062993-22-012303","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000106299322012303/form4.xml","form_type":"4"}},{"id":2307762,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2022-04-04T20:15:43.000Z","date":"2022-04-01","kind":"purchase","acquired":true,"shares":10000,"price":0.7474,"value":7474.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.722 to $0.758. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."}],"balance_after":52081,"source":{"system":"sec-edgar","filing":"0001209191-22-022336","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919122022336/doc4.xml","form_type":"4"}},{"id":2440132,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-07T22:09:20.000Z","date":"2022-01-05","kind":"grant","acquired":true,"shares":2214,"price":9.03,"value":19992.42,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $20,000 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director."}],"balance_after":2214,"derivative":{"exercise_price":13.19,"expiration_date":"2032-01-05","underlying":"Common Stock","underlying_shares":2214},"source":{"system":"sec-edgar","filing":"0000899243-22-001378","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924322001378/doc4.xml","form_type":"4"}},{"id":2597975,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-08-18T20:55:51.000Z","date":"2021-08-17","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option will vest and become exercisable in full on August 17, 2022 subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":7500,"derivative":{"exercise_price":13.69,"expiration_date":"2031-08-17","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-21-033468","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924321033468/doc4.xml","form_type":"4"}},{"id":2710111,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-17T21:04:27.000Z","date":"2021-05-12","kind":"grant","acquired":true,"shares":8300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option vests on the earlier of (a) May 12, 2022 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company."}],"balance_after":8300,"derivative":{"exercise_price":10.34,"expiration_date":"2031-05-12","underlying":"Common Stock","underlying_shares":8300},"source":{"system":"sec-edgar","filing":"0001192482-21-000439","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000119248221000439/edgar.xml","form_type":"4"}},{"id":2881257,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-03T22:00:27.000Z","date":"2021-02-01","kind":"grant","acquired":true,"shares":310000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option vest in equal monthly installments over the four years after February 1, 2021."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":310000,"derivative":{"exercise_price":5.98,"expiration_date":"2031-01-31","underlying":"Ordinary Shares","underlying_shares":310000},"source":{"system":"sec-edgar","filing":"0001209191-21-007312","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919121007312/doc4.xml","form_type":"4"}},{"id":2881256,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-03T22:00:27.000Z","date":"2021-02-01","kind":"grant","acquired":true,"shares":27731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest in 12 equal monthly installments commencing on February 1, 2021."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":27731,"derivative":{"exercise_price":5.98,"expiration_date":"2031-01-31","underlying":"Ordinary Shares","underlying_shares":27731},"source":{"system":"sec-edgar","filing":"0001209191-21-007312","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919121007312/doc4.xml","form_type":"4"}},{"id":2888399,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-01T21:15:15.000Z","date":"2021-01-29","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"124,407 shares subject to this option vested on January 15, 2019 and the remaining shares vest in equal monthly installments over the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":426185,"derivative":{"exercise_price":2.44,"expiration_date":"2028-02-06","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-006430","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919121006430/doc4.xml","form_type":"4"}},{"id":2888398,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2021-02-01T21:15:15.000Z","date":"2021-01-29","kind":"exercise","acquired":true,"shares":10000,"price":2.44,"value":24400.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":42081,"source":{"system":"sec-edgar","filing":"0001209191-21-006430","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919121006430/doc4.xml","form_type":"4"}},{"id":2909399,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2021-01-12T21:49:26.000Z","date":"2021-01-11","kind":"tax_withholding","acquired":false,"shares":3706,"price":6.72,"value":24904.32,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of RSUs and does not represent a sale by the Reporting Person."}],"balance_after":32081,"source":{"system":"sec-edgar","filing":"0001209191-21-003254","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919121003254/doc4.xml","form_type":"4"}},{"id":2909398,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2021-01-12T21:49:26.000Z","date":"2021-01-08","kind":"grant","acquired":true,"shares":10667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"shares","element":"transactionShares","label":"F2","text":"On January 16, 2019, the Reporting Person was granted certain performance-based Restricted Share Units (\"RSUs\"), the vesting of which was subject to the achievement of certain performance criteria. As of the transaction date, the first of three performance criteria was met, resulting in the vesting of 10,667 RSUs."}],"balance_after":35787,"source":{"system":"sec-edgar","filing":"0001209191-21-003254","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919121003254/doc4.xml","form_type":"4"}},{"id":2915917,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-06T21:28:08.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":1314,"price":13.31,"value":17489.34,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $17,500 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director."}],"balance_after":1314,"derivative":{"exercise_price":17.93,"expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":1314},"source":{"system":"sec-edgar","filing":"0000899243-21-000691","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924321000691/doc4.xml","form_type":"4"}},{"id":2999343,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-10-27T21:37:15.000Z","date":"2020-10-27","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option will vest and become exercisable in full on October 27, 2021 subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":7500,"derivative":{"exercise_price":13.52,"expiration_date":"2030-10-27","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-20-029337","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320029337/doc4.xml","form_type":"4"}},{"id":3019731,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-09-30T17:52:00.000Z","date":"2020-09-29","kind":"grant","acquired":true,"shares":16600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option was granted on July 16, 2020 subject to stockholder approval, which was obtained at the Company's special meeting of stockholders on September 29, 2020. The vesting commencement date for the option is July 16, 2020, and the option vests in equal monthly installments over 36 months, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date."}],"balance_after":16600,"derivative":{"exercise_price":11.9,"expiration_date":"2030-07-16","underlying":"Common Stock","underlying_shares":16600},"source":{"system":"sec-edgar","filing":"0001192482-20-000738","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000119248220000738/edgar.xml","form_type":"4"}},{"id":3110334,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-15T21:03:32.000Z","date":"2020-06-11","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"124,407 shares subject to this option vested on January 15, 2019 and the remaining shares vest in equal monthly installments over the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":436185,"derivative":{"exercise_price":2.44,"expiration_date":"2028-02-06","underlying":"Ordinary Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-036661","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919120036661/doc4.xml","form_type":"4"}},{"id":3110333,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Ordinary Shares","published_at":"2020-06-15T21:03:32.000Z","date":"2020-06-11","kind":"exercise","acquired":true,"shares":10000,"price":2.44,"value":24400.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":25120,"source":{"system":"sec-edgar","filing":"0001209191-20-036661","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919120036661/doc4.xml","form_type":"4"}},{"id":3182865,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T20:26:00.000Z","date":"2020-04-01","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest in equal monthly installments over the four years after April 1, 2020."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":150000,"derivative":{"exercise_price":7.05,"expiration_date":"2030-03-31","underlying":"Ordinary Shares","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-20-023123","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919120023123/doc4.xml","form_type":"4"}},{"id":3318620,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-01-07T00:09:15.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":2704,"price":6.47,"value":17494.88,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $17,500 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director."}],"balance_after":2704,"derivative":{"exercise_price":9.87,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":2704},"source":{"system":"sec-edgar","filing":"0000899243-20-000631","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924320000631/doc4.xml","form_type":"4"}},{"id":3317971,"issuer":{"id":94933,"kind":"organization","name":"Orchard Therapeutics plc","symbol":"ORTX"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-06T21:24:17.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest in equal monthly installments over the four years after January 2, 2020."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":200000,"derivative":{"exercise_price":13.58,"expiration_date":"2030-01-01","underlying":"Ordinary Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-20-001811","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000120919120001811/doc4.xml","form_type":"4"}},{"id":3476807,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-27T23:36:09.000Z","date":"2019-06-26","kind":"grant","acquired":true,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 26, 2020 or the date of the 2020 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company."}],"balance_after":27000,"derivative":{"exercise_price":1.25,"expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0000899243-19-018480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000089924319018480/doc4.xml","form_type":"4"}},{"id":3500745,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-05T22:50:08.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":6073,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option will vest and become exercisable in full on June 5, 2020 subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":6073,"derivative":{"exercise_price":10.67,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":6073},"source":{"system":"sec-edgar","filing":"0000899243-19-015668","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924319015668/doc4.xml","form_type":"4"}},{"id":3901386,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-07T21:44:15.000Z","date":"2018-06-06","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 6, 2019  or the date of the 2019 annual meeting of stockholders, subject to the director's continued service on the board of directors, provided that, all shares shall become fully vested upon a change in control of the Company."}],"balance_after":20000,"derivative":{"exercise_price":6.79,"expiration_date":"2028-06-06","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-18-015560","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000089924318015560/doc4.xml","form_type":"4"}},{"id":3903544,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-07T00:02:38.000Z","date":"2018-06-05","kind":"grant","acquired":true,"shares":6073,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option will vest and become exercisable in full on June 5, 2019, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":6073,"derivative":{"exercise_price":11.54,"expiration_date":"2028-06-05","underlying":"Common Stock","underlying_shares":6073},"source":{"system":"sec-edgar","filing":"0000899243-18-015330","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924318015330/doc4.xml","form_type":"4"}},{"id":4273381,"issuer":{"id":5634,"kind":"organization","name":"Larimar Therapeutics, Inc."},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-23T20:09:30.000Z","date":"2017-06-21","kind":"grant","acquired":true,"shares":14500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options were issued under the nonemployee director compensation policy and will vest in full upon the earlier of June 21, 2018 or the date of the 2018 annual meeting of stockholders, subject to the director's continued service on the board of directors."}],"balance_after":14500,"derivative":{"exercise_price":3.95,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":14500},"source":{"system":"sec-edgar","filing":"0000899243-17-017076","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242616/000089924317017076/doc4.xml","form_type":"4"}},{"id":4423064,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-27T19:01:55.000Z","date":"2017-02-23","kind":"grant","acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter."}],"balance_after":30000,"derivative":{"exercise_price":23.75,"expiration_date":"2027-02-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001179110-17-003322","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/792977/000117911017003322/edgar.xml","form_type":"4"}},{"id":4423063,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2017-02-27T19:01:55.000Z","date":"2017-02-23","kind":"grant","acquired":true,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\")."},{"field":"shares","element":"transactionShares","label":"F4","text":"These shares of Common Stock are issuable pursuant to a performance-based RSU grant under a long-term incentive program under the Plan and will be earned, if at all, based on achievement of certain relative total stockholder return targets over the three year performance period ending December 31, 2019, subject to continuation of a business relationship with the grantee through the conclusion of the performance period. The number above represents the target number of shares that may be delivered  pursuant to the award (\"Target Award\"); however, the amount that vests could range from zero to 150% of the Target Award."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."}],"balance_after":138195,"source":{"system":"sec-edgar","filing":"0001179110-17-003322","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000117911017003322/edgar.xml","form_type":"4"}},{"id":4423062,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":35380,"kind":"person","name":"THOMAS FRANK E","position":1,"cik":"0001242616","reported_name":"THOMAS FRANK E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & COO"}}],"security":"Common Stock","published_at":"2017-02-27T19:01:55.000Z","date":"2017-02-23","kind":"grant","acquired":true,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Third Amended and Restated 2007 Equity Incentive Plan (as amended the \"Plan\") and will vest in three equal annual installments with the first installment vesting on February 23, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."}],"balance_after":126195,"source":{"system":"sec-edgar","filing":"0001179110-17-003322","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000117911017003322/edgar.xml","form_type":"4"}}]}